Dear Mike,
Following is synopsis of ProtoKinetix’ discovery that you requested:
Over the last 8-years, ProtoKinetix has demonstrated repeatedly the protective nature of this very small, stable molecule patented and trademarked AAGP™. This glyco peptide functions as a powerful agent that prevents inflammation. AAGP™ has been examined and explored by numerous scientists, research laboratories, universities and corporations with consistently impressive results. These anti-inflammatory properties can treat a whole array of auto-immune diseases including Type 1 Diabetes, Rheumatoid Arthritis, Lupus, Uveitis, etc. The damage triggered by most diseases is caused by inflammation.
ProtoKinetix has tested and had independent trials on a wide variety of hostile (inflammatory inducing) agents against a large number of cell types. Every one of the numerous cell lines have resulted in consistent protection against stressful conditions that have been introduced. Some of the hostile agents tested are:
• All bands of ultra violet radiation
• Oxidative stresses
• Starvation
• Cryopreservation
• Inflammation caused by direct application of Interleukin 1 Beta
• Hydrogen Cyanide
The potential of this molecule lies in the development of therapeutic drugs for diseases where the containment of inflammation is critical. There are few alternatives for the treatment of chronic inflammatory diseases without severe side effects.
The National Institute of Chemistry, in France, showed that AAGP™ was non-toxic even in high concentrations. It is anticipated that further toxicity trials will be required for the fast track regulatory approval process. This molecule is soluble in almost any type of formulation, including those that are alcohol, water and fat based. The very small size of AAGP™ (580-Da) gives it a proven capacity for barrier penetration.
Extensive testing of the storage based platelets, done by Etablissement Francais du Sang-Alsace (EFS) demonstrated that platelets treated with AAGP™ could be stored for 21-days with no clotting or coagulation. Currently blood platelets have a maximum shelf life of 4 ½-days. EFS’ findings indicated that treatment with AAGP™ may enable platelets stored at refrigeration temperatures to have a useful shelf life of 28-days.
Recently, the University of British Columbia has received excellent results from their use of AAGP™ in and eye inflammation study. Dr. K. Gregory-Evans, a leading professor of ophthalmology, is championing ProtoKinetix’ cause in live animal trials and has demonstrated that AAGP™ will penetrate through the cornea to the retina. These findings represent a major step in the development of a potent, non-steroidal, anti-inflammatory drug to treat the many forms of eye inflammation.
The Alberta Diabetes Institute of the University of Alberta Faculty of Medicine and Dentistry developed the Edmonton Protocol for islet cell transplants. As one of the world’s leading Diabetes researchers, the Institute found that using AAGP™ during the Protocol resulted in a 300% increase in islet cell survivability and insulin production.
These consistent results have been evidenced in the protection against radiation and the post thaw efficacy of cryopreserved stem cells. Over the last 8-years and scores of different cell lines tested, the mortality of cells treated with AAGP™ has decreased from between 300% and 500%.
In conclusion, ProtoKinetix believes that the heavy lifting has been done and the evidence of the value of AAGP™ as a protective agent and anti-inflammatory has been strongly demonstrated. Mechanistic studies are underway at the University of British Columbia and the Company is actively seeking partners in specific disease treatment areas. We thank you for your interest in ProtoKinetix and we would appreciate any suggestions or help that you may have available to assist in the realization of the significant monetary value available.
My contact information is:
Keith Henderson
Co-Founder
Office - 604.926.6607
Mobile - 604-551-9947
Email - khenderson@standardbankcorp.com
Web site - www.protokinetix.com
Regards,
Keith